Overview

Maintenance Therapy With Treprilimumab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

Status:
Recruiting

Trial end date:
2029-04-28

Target enrollment:

Participant gender:

Summary

The aim of this study is to investigate the efficacy and safety of the "capecitabine combined with trepril monoclonal antibody maintenance regimen" in improving the first-line treatment of recurrent and metastatic nasopharyngeal carcinoma after receiving remission through chemotherapy combined with anti PD-1 monoclonal antibody standard regimen.

Phase:

Phase 3

Details

Lead Sponsor:

XIANG YANQUN

Collaborators:

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Zhujiang Hospital

Treatments:

Capecitabine